ArticleCell death & disease2026
Knockdown of endothelial Serpine1 improves stroke recovery by attenuating peri-infarct blood flow and blood-brain barrier disruption.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Focal stroke leads to complex changes in the cerebral microcirculation in surviving brain tissues that strongly influence functional recovery. The gene Serpine1 and its protein product Plasminogen Activator-Inhibitor-1 (PAI-1), are highly upregulated in endothelial cells after stroke, are known to inhibit clot breakdown and are an established biomarker of cardiovascular disease in humans. Therefore, we hypothesized that inhibiting this pathway specifically within brain endothelial cells could be beneficial for stroke recovery by promoting fibrinolysis and cerebral blood flow (CBF). Using longitudinal in vivo imaging, we first show in wild-type mice that focal ischaemic stroke leads to a transient reduction in peri-infarct CBF at 6 h (~41%), which is then followed by hyperperfusion at 3 days (~29%). Contrary to expectation, viral knockdown of Serpine1 in brain endothelial cells led to a persistent reduction in peri-infarct capillary width (~20-37%) and red blood cell velocity (~36-50%) over this time. Consistent with this effect on CBF, topical application of PAI-1 increased capillary diameter and flow. Of note, lowered peri-infarct CBF in Serpine1 knockdown mice appeared to play a protective role in stroke recovery since it attenuated deleterious blood-brain barrier disruption and pro-inflammatory gene expression. In agreement with this, Serpine1 knockdown mice displayed enhanced recovery of sensory evoked cortical responses, as well as improved cognitive and sensorimotor function relative to wild-type mice. These findings suggest that endothelial Serpine1/PAI-1 signalling can influence vessel tone and highlight its therapeutic potential in promoting stroke recovery. Further, our data challenge the assumption that increased CBF after the hyper-acute phase of stroke is better for recovery and suggest that carefully tuning flow, rather than maximizing it, may be an optimal strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.